Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
Supplier batch spec · ≥97% (short bioregulator peptide)
Cyclic and Neuropeptide Research CompoundsSKU: CP-PE10
PE 22-28 10mg
≥97% (short bioregulator peptide)
Related PeptidesDB entry (same owner)
peptidesdb.org
/p/pe-22-28
€32.49In Stock
Delivers to EU in 3-7 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
1
Total: €32.49
Free shipping on orders over €200
Research-grade PE 22-28. ≥98% supplier batch specification; selected lots independently tested (99.4% avg across published reports). Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
Volume PricingApplied automatically at checkout
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €32.49 | €32.49 | -- |
| 3+ | €30.87 | €92.60 | 5% off |
| 5+Most Popular | €29.24 | €146.21 | 10% off |
| 10+ | €27.62 | €276.17 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Purity HPLC
99.4% average HPLC purity across our published lab reports
Third-Party Tested
Janoshik report published when available
Fast Shipping
24h dispatch, EU-wide shipping from €4.99
Third-Party Tested
Supplier batch specification on every product; independent Janoshik report on selected lots
Last reviewed: 2026-07-22
About PE 22-28 10mg
PE-22-28 is a synthetic peptide fragment derived from the spadin protein, which is itself derived from the propeptide of the neurotensin receptor type 3 (NTSR3/sortilin). Spadin was originally identified as an endogenous blocker of TREK-1 (TWIK-related K+ channel 1), a two-pore-domain potassium channel expressed throughout the CNS that has been identified as a potential target for antidepressant pharmacology. PE-22-28 is an optimized synthetic peptide that retains TREK-1 antagonism in a shorter, more stable sequence.
The TREK-1 connection to depression comes from the observation that TREK-1 knockout mice display a depression-resistant phenotype, and that conventional antidepressants (SSRIs, tricyclics) partially inhibit TREK-1. The hypothesis is that TREK-1 inhibition contributes to antidepressant efficacy. Spadin and PE-22-28, as endogenous and synthetic TREK-1 blockers respectively, allow investigation of this hypothesis without the polypharmacology of conventional antidepressants.
Published research on PE-22-28 in rodent models shows antidepressant-like effects in forced swim and tail suspension tests, as well as in chronic mild stress models of depression. These effects have been observed at doses that appear to have good CNS penetration. The peptide represents a relatively selective pharmacological tool for studying TREK-1's role in mood regulation compared to genetic approaches.
Specifications
| Parameter | Value |
|---|---|
| Compound | PE-22-28 (Spadin-derived TREK-1 antagonist) |
| Amount per Vial | 10mg |
| Purity | ≥98% (supplier batch spec; 99.4% avg across independently tested lots) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | -20°C; 2-8°C after reconstitution |
Storage
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution and use within 28 days. Stable for 24+ months as lyophilized powder.
What is TREK-1 and why is it relevant to antidepressant research?
TREK-1 (TWIK-related K+ channel 1, KCNK2) is a two-pore-domain "background" potassium channel that sets the resting membrane potential in neurons and is modulated by temperature, mechanical stretch, lipids, and various neurotransmitter signaling. TREK-1 knockout mice show reduced depression-like behavior and resistance to stress-induced anhedonia. Conventional antidepressants including SSRIs and tricyclics partially inhibit TREK-1 in addition to their primary targets. This led to the hypothesis that TREK-1 inhibition contributes to antidepressant efficacy, and spadin/PE-22-28 allow testing this hypothesis with more selective TREK-1 antagonists.
What is the evidence for PE-22-28 having antidepressant effects?
Published rodent studies by Mazella's group and others have shown PE-22-28 produces antidepressant-like effects in standard behavioral tests (forced swim test, tail suspension test) and in chronic mild stress models. The effects were observed at IP or IV doses and appeared to involve TREK-1-related mechanisms. The compound also showed effects on hippocampal neurogenesis in some studies. All evidence is preclinical -- no clinical trials in humans have been conducted. The data supports PE-22-28 as a useful tool for TREK-1 research in mood biology contexts.
How does PE-22-28 compare to conventional antidepressants for research purposes?
Conventional antidepressants (SSRIs, SNRIs, tricyclics) affect multiple targets -- monoamine transporters, various receptors, and ion channels including TREK-1. This polypharmacology makes it difficult to attribute specific effects to TREK-1 modulation. PE-22-28's relative selectivity for TREK-1 makes it more useful for determining which antidepressant-related effects are specifically TREK-1-mediated versus those requiring monoaminergic mechanisms. This specificity is valuable for mechanistic research even if PE-22-28 is not being developed as a clinical antidepressant itself.
PE-22-28 is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Specification Summary
FormLyophilized Powder
Storage-20\u00B0C
About PE 22-28 10mg
PE-22-28 is a synthetic peptide fragment derived from the spadin protein, which is itself derived from the propeptide of the neurotensin receptor type 3 (NTSR3/sortilin). Spadin was originally identified as an endogenous blocker of TREK-1 (TWIK-related K+ channel 1), a two-pore-domain potassium channel expressed throughout the CNS that has been identified as a potential target for antidepressant pharmacology. PE-22-28 is an optimized synthetic peptide that retains TREK-1 antagonism in a shorter, more stable sequence.
The TREK-1 connection to depression comes from the observation that TREK-1 knockout mice display a depression-resistant phenotype, and that conventional antidepressants (SSRIs, tricyclics) partially inhibit TREK-1. The hypothesis is that TREK-1 inhibition contributes to antidepressant efficacy. Spadin and PE-22-28, as endogenous and synthetic TREK-1 blockers respectively, allow investigation of this hypothesis without the polypharmacology of conventional antidepressants.
Published research on PE-22-28 in rodent models shows antidepressant-like effects in forced swim and tail suspension tests, as well as in chronic mild stress models of depression. These effects have been observed at doses that appear to have good CNS penetration. The peptide represents a relatively selective pharmacological tool for studying TREK-1's role in mood regulation compared to genetic approaches.
Specifications
| Parameter | Value |
|---|---|
| Compound | PE-22-28 (Spadin-derived TREK-1 antagonist) |
| Amount per Vial | 10mg |
| Purity | ≥98% (supplier batch spec; 99.4% avg across independently tested lots) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or saline |
| Storage | -20°C; 2-8°C after reconstitution |
Storage
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution and use within 28 days. Stable for 24+ months as lyophilized powder.
What is TREK-1 and why is it relevant to antidepressant research?
TREK-1 (TWIK-related K+ channel 1, KCNK2) is a two-pore-domain "background" potassium channel that sets the resting membrane potential in neurons and is modulated by temperature, mechanical stretch, lipids, and various neurotransmitter signaling. TREK-1 knockout mice show reduced depression-like behavior and resistance to stress-induced anhedonia. Conventional antidepressants including SSRIs and tricyclics partially inhibit TREK-1 in addition to their primary targets. This led to the hypothesis that TREK-1 inhibition contributes to antidepressant efficacy, and spadin/PE-22-28 allow testing this hypothesis with more selective TREK-1 antagonists.
What is the evidence for PE-22-28 having antidepressant effects?
Published rodent studies by Mazella's group and others have shown PE-22-28 produces antidepressant-like effects in standard behavioral tests (forced swim test, tail suspension test) and in chronic mild stress models. The effects were observed at IP or IV doses and appeared to involve TREK-1-related mechanisms. The compound also showed effects on hippocampal neurogenesis in some studies. All evidence is preclinical -- no clinical trials in humans have been conducted. The data supports PE-22-28 as a useful tool for TREK-1 research in mood biology contexts.
How does PE-22-28 compare to conventional antidepressants for research purposes?
Conventional antidepressants (SSRIs, SNRIs, tricyclics) affect multiple targets -- monoamine transporters, various receptors, and ion channels including TREK-1. This polypharmacology makes it difficult to attribute specific effects to TREK-1 modulation. PE-22-28's relative selectivity for TREK-1 makes it more useful for determining which antidepressant-related effects are specifically TREK-1-mediated versus those requiring monoaminergic mechanisms. This specificity is valuable for mechanistic research even if PE-22-28 is not being developed as a clinical antidepressant itself.
PE-22-28 is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland, Israel, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
Frequently Asked
Research Library
Related Research Articles
Frequently researched together
Combined Price
€126.46
PE 22-28 10mg€32.49
1